Safety, Tolerability and Pharmacodynamic Effect of ARO-AAT
Status:
Active, not recruiting
Trial end date:
2022-07-13
Target enrollment:
Participant gender:
Summary
The purpose of AROAAT2001 (SEQUOIA) is to evaluate the safety, efficacy and tolerability of
multiple doses of the investigational product, ARO-AAT, administered subcutaneously to
participants with alpha-1 antitrypsin deficiency (AATD).